Immunomodulator for disease-modifying therapy of multiple sclerosis
Updated · Methodology
First line
Relapsing-remitting multiple sclerosis in adults. Per 2022 and SEN 2024 – moderate-efficacy disease-modifying therapy. Dose: 120 mg twice daily for 7 days, then 240 mg twice daily. Take with food – reduces flushing seen in 30–40% during the first weeks. Baseline: JC virus serology, CBC, lymphocytes, ALT.
Sources
ICD-10: G35 · ICD-11: 8A40
The drug is promoted for these uses outside international guidelines. Each entry below is analyzed against AEMPS, FDA, EMA, Cochrane and major RCTs.
Not recommended
Dimethyl fumarate is sometimes promoted in biohacking circles as an Nrf2 activator for anti-aging and detox. Nrf2 activation is described in vitro and in animal models, but clinical benefit in adults without multiple sclerosis or moderate psoriasis is not confirmed. In healthy adults it causes marked flushing, GI distress (diarrhea, nausea 30–40%), and lymphopenia with risk of progressive multifocal leukoencephalopathy (PML – rare but fatal). If prescribed for longevity without MS or moderate-severe psoriasis, consider getting a second opinion.
Dimethyl fumarate is converted to monomethyl fumarate after oral dosing – activates the Nrf2 transcription factor, triggers antioxidant response, and suppresses pro-inflammatory NF-κB signaling. Peripherally reduces cytotoxic T cells and pro-inflammatory monocytes. Exact mechanism in MS is incompletely understood. DEFINE and CONFIRM (NEJM 2012) – 44–53% reduction in annualized relapse rate vs placebo.
Not recommended in pregnancy. Effective contraception in women of reproductive age. Discontinue before planned conception.
Not recommended. No milk excretion data. Hale L4. Consider alternative or pause therapy during breastfeeding.
Reference information, not a clinical decision. Discuss feeding pauses or changes with your physician or an IBCLC.
Opens the checker prefilled with this drug. Pick the second one from your regimen.
Summary of a multi-drug list →
Medicine list: everything you take in one place →
Dimethyl Fumarate is evaluated for the following indications with varying evidence strength: Multiple sclerosis (evidence tier A), Anti-aging and longevity (evidence tier D). See the full indication matrix with dosing and citations above on this page.
Common side effects of Dimethyl Fumarate (≥ 1 in 100): Flushing 30–40% in first weeks, Diarrhea, nausea, Abdominal pain, Pruritus, Lymphopenia, Elevated ALT. See the Safety section for uncommon and serious reactions.
Not recommended in pregnancy. Effective contraception in women of reproductive age. Discontinue before planned conception.
Not recommended. No milk excretion data. Hale L4. Consider alternative or pause therapy during breastfeeding.
Dimethyl Fumarate is contraindicated in: Hypersensitivity; Confirmed or suspected progressive multifocal leukoencephalopathy; Severe lymphopenia <0.5 × 10⁹/L for >6 months; Pregnancy and breastfeeding. Full list in the Safety section.
Direct links to regulator labels. Open in a new tab.
Leflunomide, Lenalidomide, Mycophenolate mofetil, Pirfenidone, Tacrolimus, Adalimumab, Pomalidomide, Sirolimus